Recce Pharmaceuticals Ltd: Appendix 4G
Recce Pharmaceuticals Ltd: Annual Report to Shareholders
Recce Pharmaceuticals Ltd: Preliminary Final Report
Recce Pharmaceuticals Ltd: Securities Trading Policy
Recce Pharmaceuticals Ltd: Application for quotation of securities - RCE
Recce Pharmaceuticals Ltd: Successful Completion of Share Purchase Plan
Recce Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Recce Pharmaceuticals Ltd: US Department of Defense Grants US $2m for R327G
Recce Pharmaceuticals Ltd: Change of Auditor
Recce Pharmaceuticals Ltd: Share Purchase Plan - Letter and Offer Booklet
Recce Pharmaceuticals Ltd: Cleansing Notice
Recce Pharmaceuticals Ltd: Application for quotation of securities - RCE
Recce Pharmaceuticals Ltd: R327 Efficacy against WHO Priority Pathogen Acinetobacter B
Recce Pharmaceuticals Ltd: Equity Raising Presentation
Recce Pharmaceuticals Ltd: Proposed issue of securities - RCE
Recce Pharmaceuticals Ltd: Placement & SPP to raise $10 million - Funded to FY26
Recce Pharmaceuticals Ltd: Trading Halt
Recce Pharmaceuticals Ltd: Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial
Recce Pharmaceuticals Ltd: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
Recce Pharmaceuticals Ltd: Ethics Approval Broadens to All Topical Infections
No Data